Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential

1. Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

Perceptive Advisors’ Stake: $588 Million

Analyst Upside Potential: 262%

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is still pre-revenue but Wall Street is piling into the stock because of a rare triple-catalyst setup in neurology. There are two major regulatory decisions that could transform the company into a commercial powerhouse in late 2026 and early 2027. In March, the FDA granted Priority Review for relutrigine in pediatric epilepsy. The PDUFA target action date is set for September 2026. Similarly, in April, the FDA accepted the NDA for ulixacaltamide with a PDUFA date of January 2027. This drug is the first positive Phase 3 program in essential tremor, a market that has seen no new innovation in decades. Recent data from the EMBRAVE trial was also positive.

In early April, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported that 71% of patients treated with elsunersen achieved a >50% reduction in motor seizures. Analysts believe the success of elsunersen and relutrigine validates Praxis’s entire precision neuroscience platform. Funds view the company’s lead programs as having a combined $20 billion potential revenue opportunity. The firm has aggressive capital management, which has eliminated the bankruptcy risk often associated with clinical-stage biotech. After a successful follow-on offering in early 2026, Praxis ended Q1 with roughly $1.5 billion in cash. This extends its runway into 2028, ensuring it can fund the commercial launches of its own drugs without further dilution.

READ NEXT: Billionaire David Tepper’s 10 Small and Midcap Stock Picks with Huge Upside Potential and 10 Best Stocks to Invest In According to Billionaire Steve Cohen.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.